{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:37:36Z","timestamp":1768282656653,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-02043-7","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:34:45Z","timestamp":1759491285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of variable-dose metformin as adjunctive therapy to insulin in adolescents with type 1 diabetes mellitus: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Cheng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"1","key":"2043_CR1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae210","volume":"9","author":"RB Conway","year":"2024","unstructured":"Conway RB, et al. Disparities in diabetes technology uptake in youth and young adults with type 1 diabetes: a global perspective. J Endocr Soc. 2024;9(1):bvae210.","journal-title":"J Endocr Soc"},{"key":"2043_CR2","doi-asserted-by":"crossref","unstructured":"Arambewela MH et al. Young-Onset Diabetes in Sri Lanka: Experience From the Developing World. J Diabetes Res, 2024. 2024: p. 7557153.","DOI":"10.1155\/jdr\/7557153"},{"key":"2043_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2841","author":"N Papadopoulou-Marketou","year":"2017","unstructured":"Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. Diabetes Metab Res Rev. 2017. https:\/\/doi.org\/10.1002\/dmrr.2841.","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"2043_CR4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S2213-8587(20)30042-5","volume":"8","author":"D Ehrmann","year":"2020","unstructured":"Ehrmann D, et al. Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes. Lancet Diabetes Endocrinol. 2020;8(5):436\u201346.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2043_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/MED.0000000000000170","volume":"22","author":"S Polsky","year":"2015","unstructured":"Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2015;22(4):277\u201382.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"12","key":"2043_CR6","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.metabol.2015.09.002","volume":"64","author":"K Kaul","year":"2015","unstructured":"Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism. 2015;64(12):1629\u201339.","journal-title":"Metabolism"},{"issue":"7","key":"2043_CR7","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1007\/s00125-013-2904-2","volume":"56","author":"SJ Cleland","year":"2013","unstructured":"Cleland SJ, et al. Insulin resistance in type 1 diabetes: what is \u2018double diabetes\u2019 and what are the risks? Diabetologia. 2013;56(7):1462\u201370.","journal-title":"Diabetologia"},{"key":"2043_CR8","doi-asserted-by":"publisher","first-page":"117955142312067","DOI":"10.1177\/11795514231206730","volume":"16","author":"A Khadilkar","year":"2023","unstructured":"Khadilkar A, Oza C, Mondkar SA. Insulin resistance in adolescents and youth with type 1 diabetes: a review of problems and solutions. Clin Med Insights Endocrinol Diabetes. 2023;16:11795514231206730.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"2043_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.878585","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, et al. Effect and safety of adding Metformin to insulin therapy in treating adolescents with type 1 diabetes mellitus: an updated meta-analysis of 10 randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:878585.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2043_CR10","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"issue":"6","key":"2043_CR11","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2015","unstructured":"Luo D, et al. Optimally estimating the sample mean from the sample size, median, mid-range and\/or mid-quartile range. Stat Methods Med Res. 2015;27(6):1785.","journal-title":"Stat Methods Med Res"},{"key":"2043_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","author":"X Wan","year":"2014","unstructured":"Wan X, et al. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"key":"2043_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"2043_CR14","doi-asserted-by":"publisher","first-page":"1353279","DOI":"10.3389\/fcdhc.2024.1353279","volume":"5","author":"S Mondkar","year":"2024","unstructured":"Mondkar S, et al. Effect of metformin adjunct therapy on cardiometabolic parameters in Indian adolescents with type 1 diabetes: a randomized controlled trial. Front Clin Diabetes Healthc. 2024;5:1353279.","journal-title":"Front Clin Diabetes Healthc"},{"issue":"3","key":"2043_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4103\/ijem.ijem_46_23","volume":"27","author":"C Oza","year":"2023","unstructured":"Oza C, et al. A pilot study to assess effect of Metformin therapy on prevention of double diabetes in Indian adolescents with type-1 diabetes. Indian J Endocrinol Metab. 2023;27(3):201\u20137.","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"2043_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1515\/jpem-2021-0704","volume":"35","author":"A Sheikhy","year":"2022","unstructured":"Sheikhy A, et al. Benefits of Metformin add-on insulin therapy (MAIT) for HbA1c and lipid profile in adolescents with type 1 diabetes mellitus: preliminary report from a double-blinded, placebo-controlled, randomized clinical trial. J Pediatr Endocrinol Metab. 2022;35(4):505\u201310.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"2043_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.261","volume":"4","author":"E Gourgari","year":"2021","unstructured":"Gourgari E, et al. Effect of metformin on the high-density lipoprotein proteome in youth with type 1 diabetes. Endocrinology, Diabetes & Metabolism. 2021;4(3):e00261.","journal-title":"Endocrinology, Diabetes & Metabolism"},{"issue":"21","key":"2043_CR18","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1001\/jama.2015.16174","volume":"314","author":"IM Libman","year":"2015","unstructured":"Libman IM, et al. Effect of metformin added to insulin on glycemic control among overweight\/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314(21):2241\u201350.","journal-title":"JAMA"},{"issue":"8","key":"2043_CR19","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1210\/jc.2019-00129","volume":"104","author":"M Cree-Green","year":"2019","unstructured":"Cree-Green M, et al. Metformin improves peripheral insulin sensitivity in youth with type 1 diabetes. J Clin Endocrinol Metab. 2019;104(8):3265\u201378.","journal-title":"J Clin Endocrinol Metab"},{"issue":"25","key":"2043_CR20","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1161\/CIRCULATIONAHA.118.035525","volume":"138","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad P, et al. Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus. Circulation. 2018;138(25):2895\u2013907.","journal-title":"Circulation"},{"issue":"12","key":"2043_CR21","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1210\/jc.2017-00781","volume":"102","author":"JJA Anderson","year":"2017","unstructured":"Anderson JJA, et al. Effect of metformin on vascular function in children with type 1 diabetes: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 2017;102(12):4448\u201356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2043_CR22","doi-asserted-by":"publisher","first-page":"e0137525","DOI":"10.1371\/journal.pone.0137525","volume":"10","author":"BU Nwosu","year":"2015","unstructured":"Nwosu BU, Randomized A, et al. Placebo-Controlled trial of adjunctive Metformin therapy in overweight\/obese youth with type 1 diabetes. PLoS ONE. 2015;10(9):e0137525.","journal-title":"PLoS ONE"},{"issue":"3","key":"2043_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/pedi.12140","volume":"16","author":"KJ Nadeau","year":"2015","unstructured":"Nadeau KJ, et al. Effects of low dose Metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study. Pediatr Diabetes. 2015;16(3):196\u2013203.","journal-title":"Pediatr Diabetes"},{"key":"2043_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7419345","volume":"2020","author":"D Yang","year":"2020","unstructured":"Yang D, et al. Effects of metformin added to insulin in adolescents with type 1 diabetes: an exploratory crossover randomized trial. J Diabetes Res. 2020;2020:2020: p. 7419345.","journal-title":"J Diabetes Res"},{"issue":"5","key":"2043_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000355513","volume":"80","author":"E Codner","year":"2013","unstructured":"Codner E, et al. Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. Horm Res Paediatr. 2013;80(5):343\u20139.","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"2043_CR26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1530\/eje.0.1490323","volume":"149","author":"S S\u00e4rnblad","year":"2003","unstructured":"S\u00e4rnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003;149(4):323\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2043_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.metabol.2013.10.002","volume":"63","author":"JJ Chillar\u00f3n","year":"2014","unstructured":"Chillar\u00f3n JJ, et al. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014;63(2):181\u20137.","journal-title":"Metabolism"},{"issue":"7581","key":"2043_CR28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature15766","volume":"528","author":"K Forslund","year":"2015","unstructured":"Forslund K, et al. Disentangling type 2 diabetes and Metformin treatment signatures in the human gut microbiota. Nature. 2015;528(7581):262\u20136.","journal-title":"Nature"},{"issue":"8","key":"2043_CR29","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.2337\/dc20-0093","volume":"43","author":"Y Morita","year":"2020","unstructured":"Morita Y, et al. Enhanced release of glucose into the intraluminal space of the intestine associated with Metformin treatment as revealed by [(18)F]fluorodeoxyglucose PET-MRI. Diabetes Care. 2020;43(8):1796\u2013802.","journal-title":"Diabetes Care"},{"issue":"5","key":"2043_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/MED.0000000000000095","volume":"21","author":"SK Malin","year":"2014","unstructured":"Malin SK, Kashyap SR. Effects of Metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):323\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2043_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.111076","volume":"207","author":"D Zhao","year":"2024","unstructured":"Zhao D, et al. The effect of Metformin on adipokines levels: a systematic review and meta-analysis of randomized-controlled trials. Diabetes Res Clin Pract. 2024;207:111076.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"2043_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/pedi.12203","volume":"16","author":"K Konrad","year":"2015","unstructured":"Konrad K, et al. Current use of Metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria. Pediatr Diabetes. 2015;16(7):529\u201337.","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"2043_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12010-018-2899-8","volume":"188","author":"P Tom\u00e1\u0161ov\u00e1","year":"2019","unstructured":"Tom\u00e1\u0161ov\u00e1 P, et al. Metabolomics based on MS in mice with diet-induced obesity and type 2 diabetes mellitus: the effect of vildagliptin, metformin, and their combination. Appl Biochem Biotechnol. 2019;188(1):165\u201384.","journal-title":"Appl Biochem Biotechnol"},{"issue":"3","key":"2043_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/10520295.2017.1406615","volume":"93","author":"G Sudhakara","year":"2018","unstructured":"Sudhakara G, et al. Caralluma fimbriata and Metformin protection of rat pancreas from high fat diet induced oxidative stress. Biotech Histochem. 2018;93(3):177\u201387.","journal-title":"Biotech Histochem"},{"issue":"4","key":"2043_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2983","volume":"34","author":"H Meng","year":"2018","unstructured":"Meng H, et al. Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2018;34(4):e2983.","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"2043_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3334","volume":"36","author":"YS Liu","year":"2020","unstructured":"Liu YS, et al. Vascular and metabolic effects of Metformin added to insulin therapy in patients with type 1 diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2020;36(6):e3334.","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"2043_CR37","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/pedi.12493","volume":"18","author":"RA Al Khalifah","year":"2017","unstructured":"Al Khalifah RA, et al. The effect of adding Metformin to insulin therapy for type 1 diabetes mellitus children: a systematic review and meta-analysis. Pediatr Diabetes. 2017;18(7):664\u201373.","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"2043_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI77812","volume":"126","author":"VT Samuel","year":"2016","unstructured":"Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12\u201322.","journal-title":"J Clin Invest"},{"key":"2043_CR39","doi-asserted-by":"publisher","first-page":"p230868","DOI":"10.1155\/2013\/230868","volume":"2013","author":"Y Mendiz\u00e1bal","year":"2013","unstructured":"Mendiz\u00e1bal Y, Llorens S, Nava E. Hypertension in metabolic syndrome: vascular pathophysiology. Int J Hypertens. 2013;2013:p230868.","journal-title":"Int J Hypertens"},{"issue":"9","key":"2043_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5551\/jat.RV17023","volume":"25","author":"T Hirano","year":"2018","unstructured":"Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25(9):771\u201382.","journal-title":"J Atheroscler Thromb"},{"issue":"9","key":"2043_CR41","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1161\/ATVBAHA.111.241463","volume":"32","author":"JD Sparks","year":"2012","unstructured":"Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2012;32(9):2104\u201312.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"24","key":"2043_CR42","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2020;41(24):2313\u201330.","journal-title":"Eur Heart J"},{"issue":"32","key":"2043_CR43","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"key":"2043_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1471-2431-13-108","volume":"13","author":"J Anderson","year":"2013","unstructured":"Anderson J, et al. Does Metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial. BMC Pediatr. 2013;13:108.","journal-title":"BMC Pediatr"},{"issue":"1","key":"2043_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/jpbs.JPBS_370_20","volume":"13","author":"SW Gillani","year":"2021","unstructured":"Gillani SW, et al. Effect of metformin on lipid profiles of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Pharm Bioallied Sci. 2021;13(1):76\u201382.","journal-title":"J Pharm Bioallied Sci"},{"issue":"2","key":"2043_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12020-020-02190-y","volume":"67","author":"S Weng","year":"2020","unstructured":"Weng S, et al. Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials. Endocrine. 2020;67(2):305\u201317.","journal-title":"Endocrine"},{"issue":"2","key":"2043_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2006.08.022","volume":"194","author":"R Cui","year":"2007","unstructured":"Cui R, et al. Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis. 2007;194(2):415\u201320.","journal-title":"Atherosclerosis"},{"issue":"2","key":"2043_CR48","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.atherosclerosis.2012.01.013","volume":"221","author":"R Cui","year":"2012","unstructured":"Cui R, et al. High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population: the JPHC study. Atherosclerosis. 2012;221(2):565\u20139.","journal-title":"Atherosclerosis"},{"issue":"10","key":"2043_CR49","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1111\/dom.14093","volume":"22","author":"EYF Wan","year":"2020","unstructured":"Wan EYF, et al. Greater variability in lipid measurements associated with cardiovascular disease and mortality: a 10-year diabetes cohort study. Diabetes Obes Metab. 2020;22(10):1777\u201388.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2043_CR50","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/cvr\/cvac124","volume":"119","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Fasting triglycerides are positively associated with cardiovascular mortality risk in people with diabetes. Cardiovasc Res. 2023;119(3):826\u201334.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"2043_CR51","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"LJ McCreight","year":"2016","unstructured":"McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426\u201335.","journal-title":"Diabetologia"},{"key":"2043_CR52","doi-asserted-by":"publisher","first-page":"1347047","DOI":"10.3389\/fphar.2024.1347047","volume":"15","author":"M Cheng","year":"2024","unstructured":"Cheng M, et al. Understanding the action mechanisms of Metformin in the gastrointestinal tract. Front Pharmacol. 2024;15:1347047.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2043_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2022.101418","volume":"69","author":"APP Calimag","year":"2023","unstructured":"Calimag APP, et al. Diabetic ketoacidosis. Dis Mon. 2023;69(3):101418.","journal-title":"Dis Mon"},{"issue":"4","key":"2043_CR54","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40272-020-00397-0","volume":"22","author":"L Castellanos","year":"2020","unstructured":"Castellanos L, et al. Management of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus. Paediatr Drugs. 2020;22(4):357\u201367.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"2043_CR55","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s10020-024-01046-9","volume":"30","author":"P Spagnolo","year":"2024","unstructured":"Spagnolo P, et al. Metabolomic signature of pediatric diabetic ketoacidosis: key metabolites, pathways, and panels linked to clinical variables. Mol Med. 2024;30(1):250.","journal-title":"Mol Med"},{"issue":"15","key":"2043_CR56","doi-asserted-by":"publisher","first-page":"12389","DOI":"10.18632\/oncotarget.24222","volume":"9","author":"C Xu","year":"2018","unstructured":"Xu C, et al. Thiazolidinediones versus metformin on improving abnormal liver enzymes in patients with type 2 diabete","journal-title":"Oncotarget"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02043-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-02043-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02043-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:06:29Z","timestamp":1759493189000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-02043-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2043"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-02043-7","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}